Possible Case: Caraco Brand 0.25 mg Digoxin Tablets Recalled
due to Size Variability
Settlement: J&J
Fined $4.5 Million for Duragesic and Risperdal Promotion
Possible Case: Tarceva (erlotinib)
New Safety WarningS Added
Possible Case: Testosterone Gel
Safety Concerns Prompt FDA Label Changes
Possible Case: Heart Attack Test Kits
Recalled Nationwide
Possible Case: Oral Sodium Phosphate
or OSP has allegedly been recalled for acute kidney injury and kidney failure.
Settlement: $89 Million Settlement Proposed
in Bextra, Celebrex Marketing Class Action
Possible Case: FDA
Mandates Additional Labeling for Over-the-Counter Pain Relievers
Possible Case: Cough and Cold Products Recalled
Sold on or After March 05, 2009
